Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, Royal Victorian Eye & Ear Hospital, East Melbourne, Victoria, Australia.
Clin Exp Ophthalmol. 2010 Mar;38(2):141-53. doi: 10.1111/j.1442-9071.2010.02228.x.
The last 2 years has seen a marked increase in the prominence of corneal collagen cross-linking as a treatment strategy for progressive keratoconus. This interest has arisen from a body of laboratory evidence documenting the biomechanical and cellular changes induced by cross-linking. The findings of this research provide a plausible rationale for its use in keratoconus to retard the progression of this common disease. The rapidly growing number of clinical reports suggests, not only a consistent stabilizing effect of cross-linking, but that a variable improvement in corneal shape and visual function may also occur in some patients. However, the marked variation in the clinical course of keratoconus, together with the challenges of accurately evaluating refractive error, visual acuity and even corneal shape in this condition, demands further evidence from randomized controlled clinical trials. The aim of this review is to summarize the theoretical basis and risks of corneal collagen cross-linking, along with the available evidence for its use in keratoconus and other corneal disease states.
在过去的两年中，角膜胶原交联作为一种治疗进行性圆锥角膜的策略，其重要性显著增加。这种兴趣源于大量的实验室证据，证明了交联诱导的生物力学和细胞变化。这些研究结果为其在圆锥角膜中的应用提供了合理的依据，以延缓这种常见疾病的进展。越来越多的临床报告表明，交联不仅具有稳定作用，而且在某些患者中，角膜形状和视觉功能也可能得到改善。然而，圆锥角膜的临床病程变化很大，再加上准确评估屈光不正、视力甚至角膜形状的挑战，这就需要来自随机对照临床试验的进一步证据。本综述的目的是总结角膜胶原交联的理论基础和风险，以及其在圆锥角膜和其他角膜疾病状态中的应用证据。
